TABLE OF CONTENTS
1 INTRODUCTION 51
1.1 OBJECTIVES OF THE STUDY 51
1.2 MARKET DEFINITION 51
1.3 OVERVIEW OF THE NORTH AMERICA VENOUS DISEASES TREATMENT MARKET 51
1.4 CURRENCY AND PRICING 53
1.5 LIMITATIONS 54
1.6 MARKETS COVERED 54
2 MARKET SEGMENTATION 59
2.1 MARKETS COVERED 59
2.2 GEOGRAPHICAL SCOPE 60
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 DBMR TRIPOD DATA VALIDATION MODEL 62
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.6 MULTIVARIATE MODELLING 66
2.7 MARKET END USER COVERAGE GRID 67
2.8 INSTRUMENT BASED LIFELINE CURVE 68
2.9 DBMR MARKET POSITION GRID 69
2.10 VENDOR SHARE ANALYSIS 71
2.11 SECONDARY SOURCES 72
2.12 ASSUMPTIONS 72
3 EXECUTIVE SUMMARY 73
4 PREMIUM INSIGHTS 76
4.1 PESTEL ANALYSIS 77
4.2 PORTER'S FIVE FORCES 78
5 NORTH AMERICA VENOUS DISEASES TREATMENT MARKET, INDUSTRY INSIGHTS 79
6 EPIDEMIOLOGY 81
7 REGULATORY FRAMEWORK 82
8 MARKET OVERVIEW 85
8.1 DRIVERS 87
8.1.1 RISING INCIDENCES OF VENOUS DISEASES 87
8.1.2 RAPID CHANGES IN LIFESTYLE LEAD TO OBESITY RESULTING IN VENOUS DISEASES 87
8.1.3 INCREASE IN THE GERIATRIC POPULATION 88
8.1.4 TECHNOLOGICALLY ADVANCEMENT IN THE TREATMENT OF VENOUS DISEASES 89
8.2 RESTRAINTS 90
8.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 90
8.2.2 INADEQUATE REIMBURSEMENT COVERAGE 90
8.3 OPPORTUNITIES 91
8.3.1 RISING AWARENESS TOWARDS VENOUS DISORDERS 91
8.3.2 NEED FOR PROPER DIAGNOSIS AND TREATMENT OF VENOUS DISEASES 91
8.3.3 GROWING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES 92
8.3.4 OCCUPATIONAL LIFESTYLE INCREASES THE NEED FOR VENOUS DISEASE TREATMENT 92
8.4 CHALLENGES 93
8.4.1 HIGH COST ASSOCIATED WITH VENOUS DISEASE TREATMENT 93
8.4.2 SIDE EFFECTS AND RISK ASSOCIATED WITH DIFFERENT TREATMENT MODES 94
9 NORTH AMERICA VENOUS DISEASES TREATMENT MARKET, BY PRODUCT TYPE 95
9.1 OVERVIEW 96
9.2 SCLEROTHERAPY INJECTION 99
9.2.1 SCLEROTHERAPY, BY TYPE 99
9.2.1.1 INTRAVENOUS 100
9.2.1.2 INTRADERMAL 100
9.2.1.3 SUBCUTANEOUS 100
9.2.2 SUBCUTANEOUS, BY APPLICATION 100
9.2.2.1 MALFORMED LYMPHED VESSELS 100
9.2.2.2 HEMORRHOIDS 100
9.2.2.3 HYDROCELES 100
9.2.2.4 OTHERS 100
9.3 ABLATION DEVICES 100
9.3.1 THERMAL ABLATION 101
9.3.1.1 RADIOFREQUENCY 102
9.3.1.1.1 CATHETER MANIPULATION SYSTEMS 102
9.3.1.1.2 TEMPERATURE CONTROLLED 102
9.3.1.1.3 FLUID COOLED 103
9.3.1.2 LIGHT 103
9.3.1.2.1 EXCIMER LASERS 103
9.3.1.2.2 COLD LASERS 103
9.3.1.3 ULTRASOUND 103
9.3.1.3.1 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) 104
9.3.1.3.2 SHOCK WAVE LITHOTRIPSY 104
9.3.1.3.3 MAGNETIC RESONANCE IMAGING GUIDED FOCUSED ULTRASOUND (MRI-FUS) 104
9.3.1.3.4 ULTRASONIC SURGICAL SYSTEMS 104
9.3.1.4 RADIATION 104
9.3.1.4.1 STEREOTACTIC BODY RADIATION THERAPY 105
9.3.1.4.2 INTENSITY-MODULATED RADIATION THERAPY 105
9.3.1.4.3 STEREOTACTIC RADIOTHERAPY & RADIOSURGERY 105
9.3.1.4.4 IMAGE GUIDED RADIATION THERAPY 105
9.3.1.4.5 INTRAVASCULAR BRACHYTHERAPY 105
9.3.1.4.6 PROTON BEAM THERAPY 105
9.3.1.5 ELECTRICAL 105
9.3.1.5.1 ELECTRICAL ABLATORS 106
9.3.1.5.2 ELECTRONIC BRACHYTHERAPY 106
9.3.1.6 MICROWAVE 106
9.3.1.7 HYDROTHERMAL 106
9.3.2 NON-THERMAL ABLATION 106
9.3.2.1 CRYOABLATION 106
9.3.2.1.1 EPIDERMAL AND SUBCUTANEOUS CRYOABLATION DEVICES 107
9.3.2.1.2 CRYOGEN SPRAY PROBE 107
9.3.2.1.3 TISSUE CONTACT PROBE 107
9.3.2.2 HYDROMECHANICAL ABLATION 107
9.4 VENOUS CLOSURE PRODUCTS 107
9.4.1 VENOUS CLOSURE PRODUCTS, BY PROCEDURE 108
9.4.1.1 INTERVENTIONAL CARDIOLOGY 108
9.4.1.2 INTERVENTIONAL RADIOLOGY 108
9.4.2 VENOUS CLOSURE PRODUCTS, BY TECHNOLOGY 108
9.4.2.1 FEMORAL ACCESS TECHNIQUE 109
9.4.2.2 RADIAL ACCESS TECHNIQUE 109
9.5 VENOUS STENTS 109
9.5.1 VENOUS STENTS, BY TECHNOLOGY 110
9.5.1.1 WALLSTENT TECHNOLOGY 110
9.5.1.2 ILIAC VEIN STENT TECHNOLOGY 110
9.5.2 VENOUS STENTS, BY APPLICATION 110
9.5.2.1 LEG 111
9.5.2.2 CHEST 111
9.5.2.3 ABDOMEN 111
9.5.2.4 OTHERS 111
9.6 MEDICATION 111
9.7 OTHERS 112
10 NORTH AMERICA VENOUS DISEASES TREATMENT MARKET, BY DISEASE TYPE 113
10.1 OVERVIEW 114
10.2 VARICOSE VEINS 117
10.3 DEEP VEIN THROMBOSIS (DVT) 117
10.4 PULMONARY EMBOLISM 118
10.5 CHRONIC VENOUS INSUFFICIENCY (CVI) 119
10.6 SUPERFICIAL THROMBOPHLEBITIS 119
10.7 OTHERS 120
11 NORTH AMERICA VENOUS DISEASES TREATMENT MARKET, BY TREATMENT TYPE 122
11.1 OVERVIEW 123
11.2 SCLEROTHERAPY 126
11.3 RADIOFREQUENCY ABLATION THERAPY 126
11.4 LASER TREATMENT 127
11.5 AMBULATORY PHLEBECTOMY 128
11.6 VEIN LIGATION AND STRIPPING 128
11.7 ANGIOPLASTY OR STENTING 129
11.8 SURGERIES 130
11.9 COMPRESSION THERAPY 130
11.10 VEINACTIVE MEDICATION 131
11.11 VENA CAVA FILTER 132
11.12 OTHER THERAPIES 133
12 NORTH AMERICA VENOUS TREATMENT DISEASES MARKET, BY END USER 134
12.1 OVERVIEW 135
12.2 HOSPITALS 138
12.3 CLINICS 138
12.4 AMBULATORY SURGICAL CENTERS 139
12.5 OTHERS 140
13 NORTH AMERICA VENOUS DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 141
13.1 OVERVIEW 142
13.2 DIRECT TENDER 145
13.3 RETAIL SALES 145
13.4 OTHERS 146
14 NORTH AMERICA VENOUS DISEASES TREATMENT MARKET, BY REGION 147
14.1 NORTH AMERICA 148
14.1.1 U.S. 158
14.1.2 CANADA 164
14.1.3 MEXICO 170
15 NORTH AMERICA VENOUS DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 176
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 176
16 SWOT ANALYSIS 177
17 COMPANY PROFILE 178
17.1 MEDTRONIC 178
17.1.1 COMPANY SNAPSHOT 178
17.1.2 REVENUE ANALYSIS 178
17.1.3 COMPANY SHARE ANALYSIS 179
17.1.4 PRODUCT PORTFOLIO 179
17.1.5 RECENT DEVELOPMENTS 179
17.2 BOSTON SCIENTIFIC CORPORATION 180
17.2.1 COMPANY SNAPSHOT 180
17.2.2 REVENUE ANALYSIS 180
17.2.3 COMPANY SHARE ANALYSIS 181
17.2.4 PRODUCT PORTFOLIO 181
17.2.5 RECENT DEVELOPMENTS 182
17.3 VARIAN MEDICAL SYSTEMS, INC. 183
17.3.1 COMPANY SNAPSHOT 183
17.3.2 COMPANY SHARE ANALYSIS 183
17.3.3 PRODUCT PORTFOLIO 184
17.3.4 RECENT DEVELOPMENT 184
17.4 STRYKER 185
17.4.1 COMPANY SNAPSHOT 185
17.4.2 REVENUE ANALYSIS 185
17.4.3 COMPANY SHARE ANALYSIS 186
17.4.4 PRODUCT PORTFOLIO 186
17.4.5 RECENT DEVELOPMENT 186
17.5 KONINKLIJKE PHILIPS N.V. 187
17.5.1 COMPANY SNAPSHOT 187
17.5.2 REVENUE ANALYSIS 187
17.5.3 COMPANY SHARE ANALYSIS 188
17.5.4 PRODUCT PORTFOLIO 188
17.5.5 RECENT DEVELOPMENT 188
17.6 ABBOTT 189
17.6.1 COMPANY SNAPSHOT 189
17.6.2 REVENUE ANALYSIS 189
17.6.3 PRODUCT PORTFOLIO 190
17.6.4 RECENT DEVELOPMENT 190
17.7 ALMA LASERS 191
17.7.1 COMPANY SNAPSHOT 191
17.7.2 PRODUCT PORTFOLIO 191
17.7.3 RECENT DEVELOPMENT 191
17.8 ANGIODYNAMICS 192
17.8.1 COMPANY SNAPSHOT 192
17.8.2 REVENUE ANALYSIS 192
17.8.3 PRODUCT PORTFOLIO 193
17.8.4 RECENT DEVELOPMENT 193
17.9 B.BRAUN MELSUNGEN AG 194
17.9.1 COMPANY SNAPSHOT 194
17.9.2 REVENUE ANALYSIS 194
17.9.3 PRODUCT PORTFOLIO 195
17.9.4 RECENT DEVELOPMENTS 195
17.10 BAYLIS MEDICAL COMPANY, INC 196
17.10.1 COMPANY SNAPSHOT 196
17.10.2 PRODUCT PORTFOLIO 196
17.10.3 RECENT DEVELOPMENT 196
17.11 BD 197
17.11.1 COMPANY SNAPSHOT 197
17.11.2 REVENUE ANALYSIS 197
17.11.3 PRODUCT PORTFOLIO 198
17.11.4 RECENT DEVELOPMENT 198
17.12 CANDELA MEDICAL 199
17.12.1 COMPANY SNAPSHOT 199
17.12.2 PRODUCT PORTFOLIO 199
17.12.3 RECENT DEVELOPMENT 199
17.13 CARL ZEISS MEDITEC AG 200
17.13.1 COMPANYSNAPSHOT 200
17.13.2 REVENUE ANALYSIS 200
17.13.3 PRODUCT PORTFOLIO 201
17.13.4 RECENT DEVELOPMENT 201
17.14 COOK 202
17.14.1 COMPANY SNAPSHOT 202
17.14.2 PRODUCT PORTFOLIO 202
17.14.3 RECENT DEVELOPMENTS 202
17.15 IMRICOR 203
17.15.1 COMPANY SNAPSHOT 203
17.15.2 REVENUE ANALYSIS 203
17.15.3 PRODUCT PORTFOLIO 204
17.15.4 RECENT DEVELOPMENT 204
17.16 OLYMPUS CORPORATION 205
17.16.1 COMPANY SNAPSHOT 205
17.16.2 REVENUE ANALYSIS 205
17.16.3 PRODUCT PORTFOILIO 206
17.16.4 RECENT DEVELOPMENT 206
17.17 OPTIMED MEDIZINISCHE INSTRUMENTE GMBH 207
17.17.1 COMPANY SNAPSHOT 207
17.17.2 PRODUCT PORTFOLIO 207
17.17.3 RECENT DEVELOPMENTS 207
17.18 PLUSMEDICA.DE 208
17.18.1 COMPANY SNAPSHOT 208
17.18.2 PRODUCT PORTFOLIO 208
17.18.3 RECENT DEVELOPMENT 208
17.19 SCITECH 209
17.19.1 COMPANY SNAPSHOT 209
17.19.2 PRODUCT PORTFOLIO 209
17.19.3 RECENT DEVELOPMENTS 209
17.20 SMITH + NEPHEW 210
17.20.1 COMPANY SNAPSHOT 210
17.20.2 REVENUE ANALYSIS 210
17.20.3 PRODUCT PORTFOLIO 211
17.20.4 RECENT DEVELOPMENT 211
17.21 SONABLATE 212
17.21.1 COMPANY SNAPSHOT 212
17.21.2 PRODUCT PORTFOLIO 212
17.21.3 RECENT DEVELOPMENT 212

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.